This CPB has been revised as follows: (i) combine non-Hodgkin lymphoma indications for bendamustine into a single category with subcategories for each type; (ii) remove hepatic lymphoma and brain metastases from solid tumors from experimental indications for bendamustine; (iii) add criteria for the continued medical necessity of bendamustine.